Both in Pharmaceuticals
TransCode Therapeutics vs Celularity
Over the past year RNAZ returned −85.1% and CELU returned −50.6%; their daily moves had a correlation of 0.05.
RNAZ −85.1% CELU −50.6%Growth of $1, one year, split-adjusted
| Metric | RNAZ | CELU |
|---|---|---|
| Price | $1.57 | $0.8171 |
| Market cap | $26.6M | $26.5M |
| Today | −3.68% | +1.82% |
| 1 month | −10.8% | −52.2% |
| 6 months | −80.0% | −14.3% |
| Year to date | −77.0% | −26.4% |
| 1 year | — | −58.1% |
| Revenue growth (YoY) | — | −5.3% |
| Gross margin | — | 56.8% |
| Net margin | — | 10.1% |
| P/E (TTM) | — | — |
| Price / sales | — | 1.4× |
| Net cash | $7.7M | -$37.1M |
| Dividend yield | — | — |
| Volatility (60d) | 75.6% | 223.1% |
| Short % of float | 8.1% | 6.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).